lundi 23 avril 2018

Onco Actu du 23 avril 2018

1. Biologie

NCI Expands Repository of Cancer Research Models: A Conversation with Drs. Doroshow and Evrard [NCI]

The Pan-Cancer Atlas: A resource 10 years in the making [Cell CrossTalk]

Spreading Cancer (Or Just Waking It Up) [In the Pipeline]

Cancer, mutations and the facts of life [The Guardian]

2.6 Etiologie - Environnement

Unbiased Perspective Of a Biochemist On Pesticide Toxicity: Glyphosate [The Scrutinizer]

3.1 Prévention - Tabac

Philip Morris Plunges the Most in a Decade on Slump in Cigarettes [Bloomberg]

4.1 Dép., diag. & prono. - Prostate

Prostate cancer breakthrough as UK team develops more accurate test [The Guardian]

4.9 Dép., diag. & prono. - Sein

Association Between Online Information-Seeking and Adherence to Guidelines for Breast and Prostate Cancer Screening [CDC]

5. Traitements

Study may explain why some triple-negative breast cancers are resistant to chemotherapy [MD Anderson Cancer Center]

5.1 Traitements - Pré-clinique

Scans could guide drug treatment in breast cancer [institute of Cancer Research]

5.10 Traitements - Essais

UK to align with EU clinical trial rules after Brexit [Cancer Research UK]

5.12 Immunothérapies

The Problem With Miracle Cancer Cures [NY Times]

5.12.1 Immunothérapies - partenariats

Tocagen Reaches Exclusive Deal in China for Brain Cancer Therapy [Xconomy]

5.12.2 Immunothérapies - CAR-T

MorphoSys supersizes IPO, bagging $208M for cancer R&D [FierceBiotech]

Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to a cool $135M [EndPoints]

5.12.5 Immunothérapies - Pharma

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies [EndPoints]

5.2 Pharma

Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer [Novartis]

5.2.1 Pharma - Partenariats

Germany's Merck seeks partners for cancer and immune system drugs [Reuters]

5.3 Traitements - FDA, EMA, NICE...

EMA initiates divorce process from the UK’s MHRA [Pharmafile]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Approves Combo Immunotherapy for Kidney Cancer [Cancer Research Catalyst]

5.4 Traitements - Economie

Science hinted that cancer patients could take less of a $148,000-a-year drug. Its maker tripled the price of a pill. [Washington Post]

5.9 AACR

AACR Annual Meeting 2018: The Biden Cancer Initiative Colloquium [Cancer Research Catalyst]

6.11 Patients

Losing my mum to breast cancer defined my radiography career [The Guardian]

6.4 Médico-éco

Want Fries With That? A Brief History Of Medical MRI, Starting With A McDonald's [Forbes]

6.6 Publications

Science's "Reproducibility Crisis" Is Being Used as Political Ammunition [Wired]

Springer Nature aims to raise 1.2 billion euros in new money in IPO [Reuters]

6.7 DMP, Big Data & applis

23andMe Wants You to Share Even More Health Data [Wired]

Medical research needs big data – Tessa Jowell gets the ball rolling [The Guardian]

6.7.1 IA/bioinformatique

Artificial intelligence will put a premium on physicians’ knowledge and decision-making skills [STAT]

6.8 Communication

Between news release hype and peer-reviewed publication, patients wait in limbo [HealthNewsReview]

In the War on Cancer, Truth Becomes a Casualty [Wall Street Journal]

6.9 Controverses

Salk puts cancer scientist Inder Verma on leave after harassment allegations, announces investigation [Science]